Fever and eosinophilia associated with voriconazole [4]

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 900-901

  Vishnubhotla, Priya ^a   Ibrahim, Rami B ^b   Abidi, Muneer Hyder ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; MEPREDNISONE; VANCOMYCIN; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ASPERGILLOSIS; CASE REPORT; EOSINOPHILIA; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LEUKOCYTOSIS; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; ANTIFUNGAL AGENTS; EOSINOPHILIA; FEVER; HUMANS; MALE; PYRIMIDINES; TRIAZOLES;

EID: 1942438645     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D404     Document Type: Letter

References (4)

1. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Rafalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmenn JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
4. Package insert. Vfend (voriconazole). New York: Pfizer, 2002.